19.09

0.63% 0.15

Syndax Pharmaceuticals Inc (SNDX)

Overview News Price History Option Chain Financials Discussions Forecast

Syndax Pharmaceuticals Inc stock is traded at $19.09, with a volume of 951.60K. It is up +0.63% in the last 24 hours and up +1.28% over the past month. Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.

Previous Close:

$18.94

Open:

$19.1

24h Volume:

951.60K

Relative Volume:

1.09

Market Cap:

$1.64B

Revenue:

$139.71M

Net Income/Loss:

$-209.36M

P/E Ratio:

-7.3992

EPS:

-2.58

Net Cash Flow:

$-160.60M

1W Performance:

-0.10%

1M Performance:

+1.28%

6M Performance:

-13.56%

1Y Performance:

+28.78%

1-Day Range:

$18.75

$19.66

1-Week Range:

$18.56

$19.66

52-Week Range:

$13.14

$25.34

Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile

Name

Syndax Pharmaceuticals Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

781-419-1400

Address

35 GATEHOUSE DRIVE, WALTHAM, MA

Employee

184

Twitter

@syndax

Next Earnings Date

2024-11-05

Latest SEC Filings

SNDX's Discussions on Twitter

Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-31-24	Downgrade	Scotiabank	Sector Outperform → Sector Perform
Dec-22-23	Initiated	Mizuho	Buy
Oct-25-23	Initiated	BofA Securities	Buy
Oct-11-23	Initiated	Goldman	Buy
Jul-27-23	Initiated	Scotiabank	Sector Outperform
Jul-11-23	Initiated	Guggenheim	Buy
Apr-17-23	Resumed	BTIG Research	Buy
Jan-31-23	Initiated	Stifel	Buy
Jan-03-23	Initiated	JP Morgan	Overweight
Jul-28-22	Resumed	B. Riley Securities	Buy
Apr-11-22	Initiated	H.C. Wainwright	Buy
Feb-15-22	Initiated	Goldman	Buy
Jun-04-21	Resumed	Robert W. Baird	Outperform
May-25-21	Initiated	Citigroup	Buy
Feb-18-21	Initiated	B. Riley Securities	Buy
Dec-03-20	Initiated	Stifel	Buy
May-22-20	Upgrade	Citigroup	Neutral → Buy
May-22-20	Downgrade	H.C. Wainwright	Buy → Neutral
May-18-20	Downgrade	Citigroup	Buy → Neutral
May-11-20	Reiterated	H.C. Wainwright	Buy
Mar-04-20	Initiated	Barclays	Overweight
Jan-13-20	Reiterated	H.C. Wainwright	Buy
Mar-08-19	Reiterated	H.C. Wainwright	Buy
Jan-04-19	Initiated	Robert W. Baird	Outperform
Jan-05-18	Initiated	B. Riley FBR, Inc.	Buy
Mar-16-17	Initiated	FBR & Co.	Outperform
Mar-02-17	Initiated	Instinet	Buy
Oct-07-16	Initiated	Guggenheim	Buy
Mar-28-16	Initiated	Citigroup	Buy
Mar-28-16	Initiated	JMP Securities	Mkt Outperform
Mar-28-16	Initiated	Morgan Stanley	Overweight

View All

Syndax Pharmaceuticals Inc Stock (SNDX) Latest News

09:01 AM

Syndax to Host ASH Investor Event in Person and via Webcast on December 9, 2024 - StockTitan

09:01 AM

09:00 AM

Syndax's Niktimvo Achieves 75% Response Rate in Pivotal GVHD Trial, New Data Shows | SNDX Stock News - StockTitan

09:00 AM

04:29 AM

Royalty Pharma plc and Syndax Pharmaceuticals Enter into $350 Million Royalty Funding Agreement for Niktimvo - Marketscreener.com

04:29 AM

04:13 AM

Syndax enters funding agreement with Royalty Pharma for Niktimvo - Pharmaceutical Technology

04:13 AM

01:45 AM

Syndax secures $350 million in royalty funding from Royalty Pharma By Investing.com - Investing.com Canada

01:45 AM

Nov 04, 2024

Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo - StockTitan

Nov 04, 2024

Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™ - StockTitan

Nov 04, 2024

(SNDX) Investment Analysis - Stock Traders Daily

Nov 04, 2024

Nov 01, 2024

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - StockTitan

Nov 01, 2024

Syndax Announces Participation in November Investor Conferences - StockTitan

Nov 01, 2024

Oct 30, 2024

Syndax Pharmaceuticals (SNDX) Set to Announce Earnings on Tuesday - MarketBeat

Oct 30, 2024

Oct 29, 2024

Syndax to Announce Third Quarter 2024 Financial Results and Host Conference Call and Webcast on November 5, 2024 - StockTitan

Oct 29, 2024

Assenagon Asset Management S.A. Buys 37,079 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat

Oct 29, 2024

Syndax Pharmaceuticals' SWOT analysis: stock poised for growth amid FDA approvals - Investing.com India

Oct 29, 2024

Oct 28, 2024

Syndax Pharmaceuticals' SWOT analysis: stock poised for growth amid FDA approvals By Investing.com - Investing.com South Africa

Oct 28, 2024

Oct 26, 2024

Syndax Pharmaceuticals (NASDAQ:SNDX) Now Covered by UBS Group - Defense World

Oct 26, 2024

Oct 25, 2024

UBS Initiates Coverage of Syndax Pharmaceuticals (SNDX) with Buy Recommendation - MSN

Oct 25, 2024

Oct 24, 2024

Syndax Pharmaceuticals' SWOT analysis: biotech stock faces pivotal moment - Investing.com India

Oct 24, 2024

Syndax Pharmaceuticals' SWOT analysis: biotech stock faces pivotal moment By Investing.com - Investing.com South Africa

Oct 24, 2024

UBS starts SMID cap biotechs with cancer, autoimmunity focus - Seeking Alpha

Oct 24, 2024

Syndax Pharmaceuticals (NASDAQ:SNDX) Earns Buy Rating from Analysts at UBS Group - MarketBeat

Oct 24, 2024

Oct 19, 2024

Inspire Investing LLC Has $410,000 Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World

Oct 19, 2024

Oct 18, 2024

State Street Corp's Strategic Acquisition in Syndax Pharmaceuticals - GuruFocus.com

Oct 18, 2024

Oct 17, 2024

Creative Planning Has $378,000 Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World

Oct 17, 2024

Oct 16, 2024

SNDX underperforms with a -0.35 decrease in share price - US Post News

Oct 16, 2024

Syndax drops as FDA extends target date for leukemia drug application - MSN

Oct 16, 2024

Oct 15, 2024

Top investors say Syndax Pharmaceuticals Inc (SNDX) ticks everything they need - SETE News

Oct 15, 2024

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by AQR Capital Management LLC - MarketBeat

Oct 15, 2024

Oct 14, 2024

Kura downgraded to hold by Stifel, prefers rival Syndax - MSN

Oct 14, 2024

Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $41.00 - MarketBeat

Oct 14, 2024

We Think Syndax Pharmaceuticals (NASDAQ:SNDX) Needs To Drive Business Growth Carefully - Simply Wall St

Oct 14, 2024

Northwestern Mutual Wealth Management Co. Invests $27,000 in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World

Oct 14, 2024

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Oct 14, 2024

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Purchased by The Manufacturers Life Insurance Company - Defense World

Oct 14, 2024

Oct 13, 2024

Dimensional Fund Advisors LP Has $1.44 Million Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat

Oct 13, 2024

Oct 11, 2024

Taking a look at what insiders are doing to gauge the Syndax Pharmaceuticals Inc (SNDX)’s direction - Knox Daily

Oct 11, 2024

Have you been able to find a good deal on Syndax Pharmaceuticals Inc’s shares? - US Post News

Oct 11, 2024

Oct 09, 2024